| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $43.5M | — |
| Cost of Revenue | $3.2M | — |
| Gross Profit | $40.3M | — |
| R&D Expense | $3.9M | -70.0% |
| SG&A Expense | $30.0M | -16.3% |
| Operating Income | -$22.4M | +54.3% |
| Pre-tax Income | -$19.3M | +58.3% |
| Income Tax | -$1.4M | — |
| Net Income | -$17.9M |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $40.7M | -6.9% |
| Short-term Investments | $11.0M | -65.9% |
| Accounts Receivable | $51.7M | — |
| Inventory | $7.6M | +260.8% |
| Current Assets | $114.6M | +44.2% |
| Total Assets | $118.8M | +44.8% |
| Current Liabilities | $33.8M | +196.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$50.6M | -31.8% |
| Capital Expenditures | $116K | -64.6% |
| Investing Cash Flow | $21.2M | +224.4% |
| Financing Cash Flow | $26.3M | -52.9% |
| Free Cash Flow | -$50.7M | -31.0% |
| EPS (Basic) | -$0.30 | +67.0% |
| EPS (Diluted) | -$0.30 | +67.0% |
| Total Liabilities |
| $34.2M |
| +186.9% |
| Stockholders' Equity | $84.7M | +20.7% |